This narrative review discusses the mechanisms of key GLP-1 RAs, including exenatide, liraglutide, and semaglutide, and examines various clinical trial data supporting their effectiveness in achieving substantial weight reduction in individuals with and without diabetes. The gene discussed is GLP1R; the disease is diabetes mellitus.